Drug Etiology of Agranulocytosis and Aplastic Anemia

DRUG INDUCED AGRANULOCYTOSIS AND APLASTIC ANEMIA: GENERAL CONSIDERATIONS: The concept of drug safety; Agranulocytosis and aplastic anemia as drug-induced diseases; Evidence for the drug induction of agranulocytosis; Evidence for the drug induction of aplastic anemia; STRATEGIES FOR OBTAINING INFORMATION ABOUT DRUG EFFECTS: Benefit, risk, the present study; THE DISEASES (by Herman Heimpel): Agranulocytosis, Aplastic anemia; THE DESIGN OF THE STUDY: Objectives, definition of cases, study base, sample size estimates, methodological considerations in the collection of data; METHODS: Definition and ascertainment of cases, selection of controls, data collection, data analysis; THE STUDY EXPERIENCE: Origins of the study, pilot study, changes in the study population, completeness of case ascertainment, definition of onset for cases of agranulocytosis, interim analyses; THE STUDY POPULATION: Agranulocytosis, Aplastic anemia, Controls, Summary; INCIDENCE OF AGRANULOCYTOSIS: The study base: overall incidence, community-acquired agranulocytosis, comments; INCIDENCE OF APLASTIC ANEMIA: The study base: overall incidence, incidence according to various factors, comments; NONNARCOTIC ANALGESIC AND NONSTEROIDAL ANTI-FLAMMATORY DRUGS; The drugs, specific methods, results, summary of results and consideration of validity, comments, conclusion; ANTI-INFECTIVE DRUGS: The drugs, specific methods, results, summary of results and consideration of validity, comments, conclusion; ANTITHYROID DRUGS: The drugs, specific methods, results, summary of results and considerations of validity, comments, conclusion; CARDIOVASCULAR DRUGS AND DIURETICS: The drugs, specific methods, results, summary of results and consideration of validity, comments, conclusion; PSYCHOTROPIC DRUGS AND ANTIHISTAMINES: The drugs, specific methods, results, summary of results and consideration of validity, comments, conclusion; MISCELLANEOUS DRUGS: The drugs, specific methods, results, summary of results and consideration of validity, comments, conclusion; FACTORS OTHER THAN DRUGS: Introduction, specific methods, results, summary of results and consideration of validity, comments, conclusion; GENERAL CONCLUSIONS: Risk estimation for diseases with multiple causes; Etiologically relevant risk intervals; Regional variation of drug-induced agranulocytosis; The strengths and limitations of the present study; Concluding remarks. Appendices; Index of Drug names.